Preferred Label : alectinib;
MeSH note : an anaplastic lymphoma kinase (Alk) inhibitor; structure in first source;
CISMeF synonym : RO5424802; CH5424802;
Is substance : O;
UNII : LIJ4CT1Z3Y;
Origin ID : C582670;
UMLS CUI : C3853921;
ATC code(s)
- MeSH indexing information
- MeSH term(s) associated for indexing
- Pharmacological action(s)
- Record concept(s)
- Semantic type(s)
- UMLS correspondences (same concept)
https://www.has-sante.fr/jcms/p_3557276/fr/alecensa-alectinib-cancer-bronchique-non-a-petites-cellules-cbnpc
2024
false
false
false
France
bronchial neoplasms
bronchial neoplasms
treatment outcome
treatment outcome
insurance, health, reimbursement
insurance, health, reimbursement
alectinib
alectinib
Adjuvant Therapy
Adjuvant Therapy
ALK Positive
ALK Positive
adult
adult
recurrence
recurrence
administration, oral
administration, oral
Tyrosine Kinase Inhibitors
Tyrosine Kinase Inhibitors
evaluation of the transparency committee
evaluation of the transparency committee
carcinoma, non-small-cell lung
carcinoma, non-small-cell lung
alectinib
alectinib
---
https://www.has-sante.fr/portail/jcms/c_2857802/fr/alecensa
https://www.has-sante.fr/portail/jcms/c_2857802/fr/alecensa-alectinib-inhibiteur-de-tyrosine-kinase
2018
false
false
false
France
French
treatment outcome
administration, oral
carcinoma, non-small-cell lung
alectinib
protein kinase inhibitors
adult
aged
antineoplastic agents
evaluation of the transparency committee
survival analysis
ALK gene rearrangement positive
guidelines for drug use
Tyrosine Kinase Inhibitors
alectinib
alectinib
carbazoles
piperidines
receptor Protein-Tyrosine kinases
Anaplastic Lymphoma Kinase
---
https://www.ema.europa.eu/medicines/human/EPAR/Alecensa
2017
false
false
false
United Kingdom
French
English
syndication feed
summary of product characteristics
package leaflet
drug evaluation
drug approval
europe
treatment outcome
alectinib
administration, oral
carcinoma, non-small-cell lung
alectinib
alectinib
protein kinase inhibitors
protein kinase inhibitors
product surveillance, postmarketing
adult
aged
drug interactions
pregnancy
breast feeding
fertility
antineoplastic agents
antineoplastic agents
drug evaluation, preclinical
Tyrosine Kinase Inhibitors
alectinib
alectinib
carbazoles
piperidines
carbazoles
piperidines
receptor Protein-Tyrosine kinases
Anaplastic Lymphoma Kinase
---
Summary Basis of Decision (SBD) for Alecensaro
Alectinib (as alectinib hydrochloride), 150 mg, capsule, oral
https://hpr-rps.hres.ca/reg-content/sommaire-motif-decision-detailTwo.php?lang=fr&linkID=SBD00332
2016
false
false
false
Canada
French
English
administration, oral
administration, oral
treatment outcome
treatment outcome
alectinib
alectinib
alectinib
alectinib
drug approval
drug approval
canada
canada
risk assessment
risk assessment
protein kinase inhibitors
protein kinase inhibitors
protein kinase inhibitors
protein kinase inhibitors
carcinoma, non-small-cell lung
carcinoma, non-small-cell lung
carcinoma, non-small-cell lung
carcinoma, non-small-cell lung
mutation
mutation
Locally Advanced Malignant Neoplasm
Locally Advanced Malignant Neoplasm
neoplasm metastasis
neoplasm metastasis
disease progression
disease progression
product surveillance, postmarketing
product surveillance, postmarketing
alectinib
alectinib
Alectinib hydrochloride (substance)
Alectinib hydrochloride (substance)
drug information
drug information
alectinib
alectinib
alectinib
alectinib
carbazoles
carbazoles
piperidines
piperidines
carbazoles
carbazoles
piperidines
piperidines
receptor Protein-Tyrosine kinases
receptor Protein-Tyrosine kinases
Anaplastic Lymphoma Kinase
Anaplastic Lymphoma Kinase
---
